Introduction to Psychedelic-assisted Therapy
The Introduction to Psychedelic-assisted Therapy is a continuing education credited training course designed for practising psychologists, psychiatrists, and other medical professionals. The course is a prerequisite for the ATMA Advanced Psychedelic-assisted Therapy (PaT) Certification Program, and
Provider
Details
Enrollment
Upcoming Cohort
Start date: September 5, 2024
Apply now →Course Overview
The Introduction to Psychedelic-assisted Therapy is a continuing education credited training course designed for practising psychologists, psychiatrists, and other medical professionals. The course is a prerequisite for the ATMA Advanced Psychedelic-assisted Therapy (PaT) Certification Program, and is accepting registrations every second month.
The course begins by redefining the psychiatric model from one of "chemical imbalance" to one rooted in the mind-body-spirit dynamic, and provides historical context for the development of psychedelic medicines. The didactic course material will cover various psychedelic medicines currently in use, including an emphasis on psilocybin, MDMA, LSD, iboga, ayahuasca, and ketamine. The course will also explore how psychedelic-assisted therapy can be integrated into and enhance existing therapeutic modalities, such as internal family systems (IFS), cognitive-behavioural therapy (CBT), somatic therapy, and eye movement desensitization and reprocessing (EMDR).
The program includes 12 lessons, 17 hours of video lectures, 4 hours of interactive Q&A, community platform membership and CE credits (valid in Canada). The training is designed to provide evidence-based tools to enhance current practice for practising social workers, counsellors, psychologists, psychiatrists and medical professionals.
About the Provider
ATMA Journey Centers is an Alberta-based Canadian pioneer in psychedelic-assisted therapy, operating clinically supervised locations across Canada while offering comprehensive psychedelic-assisted therapy training programs (ATMA CENA) covering psilocybin, MDMA, and ketamine for healthcare professionals. With 740+ training alumni and 800+ community members, ATMA also operates a clinic network partnership program and Phase II psilocybin clinical trials with Health Canada approval.
Course Details
- Price$1,600
- FormatLive Classes
- LevelProfessional
- Duration21 Hours· 12 modules
- LanguageEnglish
- AccreditationCE
- Skillsevidence-based toolspsychedelic therapymind-body-spirit dynamicpsychiatric modelpsychedelic medicinestherapeutic modalitiesinternal family systemscognitive-behavioral therapysomatic therapyeye movement desensitizationreprocessing
- ProviderAtma Journey
You will be redirected to the provider's website